Skip to main content
XCUR
NASDAQ Life Sciences

Exicure Appoints Two New Directors, Forms Compensation Committee Amidst Nasdaq Compliance Concerns

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$2.03
Mkt Cap
$12.939M
52W Low
$1.71
52W High
$9.5
52W Position info
19% above low
Off High info
79% below high
Rel. Volume info
4.0× avg
Market data snapshot near publication time

XCUR sits 19% above its 52-week low of $1.71 on elevated volume (4.0× avg).

Summary

Exicure, Inc. announced board changes, including the resignation of one director, the appointment of two new directors (one independent), and the formation of a Compensation Committee, which may address ongoing Nasdaq compliance issues.


Key Events · Executive and Board Changes · XCUR

  • Director Resignation

    Ham Jung Kyu resigned from the Board of Directors, effective June 30, 2026. The resignation was not due to any disagreement.

  • Board Expansion

    The Board increased its size from five to six directors, effective June 30, 2026.

  • New Director Appointments

    Go Jin Young was appointed to fill the vacancy, and Han Eui Seok was appointed to the newly created directorship.

  • Independent Director Added

    Han Eui Seok was determined to qualify as an independent director under Nasdaq Listing Rules.


Analysis · XCUR · Life Sciences

This 8-K details significant changes to Exicure's Board of Directors and corporate governance structure. The appointment of an independent director and the formation of a Compensation Committee are important steps, especially given the company's recent disclosure of a Nasdaq non-compliance notice in its Q1 2026 10-Q. These actions could be part of an effort to strengthen governance and address the requirements for continued listing on Nasdaq, which is critical for a company facing severe financial distress and a going concern warning.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, XCUR was trading at $2.03 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12.9M. The 52-week trading range was $1.71 to $9.50. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

XCUR - Latest Insights

XCUR
Nov 20, 2026, 5:13 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.9001
Real-time Price: $0.9905 info
Change: +$0.0904 (+10%) info
Market Cap: $5.892M info
XCUR
Nov 20, 2026, 1:00 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.920
Real-time Price: $0.9905 info
Change: +$0.0705 (+8%) info
Market Cap: $5.892M info
XCUR
Nov 16, 2026, 4:00 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.07
Real-time Price: $0.9905 info
Change: -$0.0795 (-7%) info
Market Cap: $5.892M info
XCUR
Nov 10, 2026, 3:50 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.08
Real-time Price: $0.9905 info
Change: -$0.0905 (-8%) info
Market Cap: $5.892M info
XCUR
Nov 10, 2026, 3:50 PM EST
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $1.08
Real-time Price: $0.9905 info
Change: -$0.0905 (-8%) info
Market Cap: $5.892M info